View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

Intron Health - AI Impact on Pharma - Thematic (20pgs) - Winners/Loser...

Our Big Pharma AI thesis is the result of ~25 interviews with industry execs & >100hrs of research. We show ~10% of OPEX could be saved by AI within a few years & conclude the recent sector rally is wholly justified & could run further. We assess the winners & losers from AI adoption and discuss in detail some of the short, mid & long-term consequences. We evaluate the various AI use cases and quantify the potential benefit they may have. We break down SG&A & R&D activities & show where AI is im...

ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Georg Tigalonov-Bjerke
  • Sten Gustafsson

Intervacc AB: 2 directors

Two Directors at Intervacc AB bought 330,000 shares at between 0.620SEK and 0.730SEK. The significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...

Bonesupport Holding AB: 1 director

A director at Bonesupport Holding AB bought 13,738 shares at 189.691SEK and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Georg Tigalonov-Bjerke

Swedish Orphan Biovitrum AB: 1 director

A director at Swedish Orphan Biovitrum AB bought 2,400 shares at 407.681SEK and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Georg Tigalonov-Bjerke
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Sten Gustafsson
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Sten Gustafsson
 PRESS RELEASE

Notice of Extraordinary General Meeting, proposed company dissolution ...

Notice of Extraordinary General Meeting, proposed company dissolution and delisting Oslo, Norway 23 February 2026 – An extraordinary general meeting of PCI Biotech Holding ASA (‘PCI Biotech’ or ‘Company’) will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 16 March 2026 at 10:00am (CET). The proposed resolutions include company dissolution and delisting from Euronext Oslo Børs. The Board of Directors’ proposed resolution to dissolve PCI Biotech is made as there is no longer any operational activity in the Company, nor is it expected that it will resume such acti...

ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Georg Tigalonov-Bjerke
  • Sten Gustafsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Georg Tigalonov-Bjerke
  • Sten Gustafsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Georg Tigalonov-Bjerke
  • Sten Gustafsson
Martial Descoutures
  • Martial Descoutures
Martial Descoutures
  • Martial Descoutures

Attendo AB: 2 directors

A director at Attendo AB bought 210,981 shares at 101.000SEK and the significance rating of the trade was 98/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch